header advert
Results 1 - 3 of 3
Results per page:
Applied filters
General Orthopaedics

Include Proceedings
Dates
Year From

Year To
Orthopaedic Proceedings
Vol. 101-B, Issue SUPP_14 | Pages 59 - 59
1 Dec 2019
Giannitsioti E Salles M Mavrogenis A Rodríguez-Pardo D Pigrau C Ribera A Ariza J Toro DD Nguyen S Senneville E Bonnet E Chan M Pasticci MB Petersdorf S Soriano A Benito N Connell NO García AB Skaliczki G Tattevin P Tufan ZK Pantazis N Megaloikonomos PD Papagelopoulos P Papadopoulos A
Full Access

Aim

Gram negative bacteria (GNB) are emerging pathogens in chronic post-traumatic osteomyelitis. However, data on multi-drug (MDR) and extensively drug resistant (XDR) GNB are sparse.

Methods

A multi-centre epidemiological study was performed in 10 countries by members of the ESGIAI (ESCMID Study Group on Implant Associated Infections). Osteosynthesis-associated osteomyelitis (OAO) of the lower extremities and MDR/XDR GNB were defined according to international guidelines. Data from 2000 to 2015 on demographics, clinical features, microbiology, surgical treatment and antimicrobial therapy were retrospectively analyzed. Cure was assessed after the end of treatment as the absence of any sign relevant to OAO. Factors associated with cure were evaluated by regression analysis.


Orthopaedic Proceedings
Vol. 100-B, Issue SUPP_17 | Pages 91 - 91
1 Dec 2018
Papadopoulos A Ribera A Mavrogenis A Rodríguez-Pardo D Bonnet E Salles M del Toro MD Nguyen S García AB Skaliczki G Soriano A Benito N Petersdorf S Pasticci MB Tattevin P Tufan ZK Chan M Connell NO Pantazis N Pigrau C Megaloikonomos PD Senneville E Ariza J Papagelopoulos P Giannitsioti E
Full Access

Aim

Data on Prosthetic joint infection (PJI) caused by multi-drug resistant (MDR) or XDR (extensively drug resistant) Gram negative bacteria (GNB) are limited. Treatment options are also restricted. We conducted a multi-national, multi-center assessment of clinical data and factors of outcome for these infections.

Method

PJI were defined upon international guidelines. Data from 2000–2015 on demographics, clinical features, microbiology, surgical treatment and antimicrobial therapy was collected retrospectively. Factors associated with treatment success were evaluated by logistic regression analysis.


Orthopaedic Proceedings
Vol. 97-B, Issue SUPP_16 | Pages 28 - 28
1 Dec 2015
Pistiki A Nikou P Giamarellos-Bourboulis E Georgitsi M Soranoglou V Galani I Kanellakopoulou K Giannitsioti E
Full Access

Prosthetic joint infections are difficult to treat due to bacterial biofilm. Our group has developed a linezolid elution system by human cancellous bone delivering high concentrations the first 48 hours (Giannitsioti et al. 53rd ICAAC, 2013: A-1050). We tested the activity of this system to inhibit growth of one ica expressing isolate of Staphylococcus epidermidis (MRSE).

At a first step, sterile mesh cylinders containing bone particles of the femoral head of healthy volunteers (MCB) were impregnated into 3mg/ml linezolid for 1, 24 and 48 hours. Then log-phase inocula of 103, 105 and 107cfu/ml were exposed to MCB at 370C for 8 days with regular readings of bacterial growth. MCB were transferred into fresh Muller-Hinton Broth (MHB) every 24h to avoid material corrosion. At a second step, to simulate the ability of the system against biofilm-coated MCB, MCB without linezolid were incubated with 103 and 105 cfu/ml for 1 and 24h. MCB were daily transferred into fresh MHB containing 100μg/ml on day 1, 15 μg/ml on day 2, 3 μg/ml on day 3 and 0.5 μg/ml on day 4.

24h linezolid impregnated MCB achieved rapid bacterial killing of the 105 cfu/ml bacterial suspension followed by re-growth (Figure, n= 5). Similar results were observed for 1h and 48h impregnation and for both tested inocula. When biofilm-coated MCB generated by 24h exposure to 105 cfu/ml were exposed to linezolid, rapid bacterial killing was achieved followed by re-growth.

Linezolid local elution may inhibit biofilm-producing MRSE only when locally eluted concentrations exceed 10μg/ml.